Evidence map›Paper›PMID 41963303›Full record

ArticleCell death & disease2026

Targeting the epigenome and the integrated stress response to normalize colorectal cancer subclonal plasticity and progression.

Lili Li, Taekyu Ha, Jing-Xin Feng, Michael DiPrima, Dunrui Wang, Parthav Jailwala, Thomas Meyer, Justin Lack, Hidetaka Ohnuki, Giovanna Tosato

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Targeting the Epigenome in Colorectal Cancer.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lili LiLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Taekyu HaLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Jing-Xin FengLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0677-2792
Michael DiPrimaLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Dunrui WangLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Parthav JailwalaAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-2943-801X
Thomas MeyerAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-7185-5597
Justin LackAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Hidetaka OhnukiLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA.
Giovanna TosatoLaboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA. tosatog@mail.nih.gov.ORCID http://orcid.org/0000-0003-1663-3227

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite therapeutic advances, metastatic colorectal cancer remains a therapeutic challenge as most patients will develop resistance to therapy and will progress. Epigenetic mechanisms are implicated in enabling the acquisition of new phenotypic traits as drivers of colorectal cancer progression, rather than new genetic mutations or expansion of existing mutant clones. It remains unclear, however, which epigenetic mechanisms sustain colorectal cancer plasticity, how they are induced, and how this plasticity generates subclonal diversity that drives the aggressive cancer phenotype. Here we identify the integrated stress response as an inducer of colorectal cancer cell plasticity, subclonal diversity, and tumor progression in the stress-surviving cells. Combined analysis of chromatin accessibility and gene transcription profiling in these cells found the emergence of an endogenous interferon response as a key phenotypic trait associated with subclonal colorectal cancer cell diversity, treatment resistance and heightened aggressiveness. We unveil a new experimental approach to successfully prevent treatment-resistant colorectal cancer progression by combining epigenetic modulators with a cereblon-dependent degrader of GSPT1, a regulator of protein synthesis, to normalize chromatin accessibility and induce colorectal cancer cell death. Collectively, our study identifies the integrated stress response as an inducer of epigenetic and transcriptional plasticity in colorectal cancer cells and highlights a successful approach to therapeutic intervention.

Indexed as

Cell PlasticityColorectal NeoplasmsEpigenomeIntegrated Stress ResponseAnimalsCell Line, TumorDisease ProgressionEpigenesis, GeneticGene Expression Regulation, NeoplasticHumans

Identifiers

PMID41963303
PMCPMC13181133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.